390 related articles for article (PubMed ID: 26806217)
1. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Radue EW; Sprenger T; Vollmer T; Giovannoni G; Gold R; Havrdova E; Selmaj K; Stefoski D; You X; Elkins J
Eur J Neurol; 2016 Feb; 23(2):412-5. PubMed ID: 26806217
[TBL] [Abstract][Full Text] [Related]
2. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Giovannoni G; Radue EW; Havrdova E; Riester K; Greenberg S; Mehta L; Elkins J
J Neurol; 2014 Feb; 261(2):316-23. PubMed ID: 24375015
[TBL] [Abstract][Full Text] [Related]
3. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
Havrdova E; Giovannoni G; Stefoski D; Forster S; Umans K; Mehta L; Greenberg S; Elkins J
Mult Scler; 2014 Apr; 20(4):464-70. PubMed ID: 24022270
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.
Arnold DL; You X; Castrillo-Viguera C
J Neurol; 2017 Aug; 264(8):1728-1734. PubMed ID: 28685353
[TBL] [Abstract][Full Text] [Related]
5. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Giovannoni G; Gold R; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; McNeill M; Amaravadi L; Sweetser M; Elkins J; O'Neill G;
Lancet Neurol; 2014 May; 13(5):472-81. PubMed ID: 24656609
[TBL] [Abstract][Full Text] [Related]
6. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
[TBL] [Abstract][Full Text] [Related]
7. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis.
Dalton CM; Miszkiel KA; Barker GJ; MacManus DG; Pepple TI; Panzara M; Yang M; Hulme A; O'Connor P; Miller DH
J Neurol; 2004 Apr; 251(4):407-13. PubMed ID: 15083284
[TBL] [Abstract][Full Text] [Related]
8. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
[TBL] [Abstract][Full Text] [Related]
9. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
10. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Zivadinov R; Dwyer MG; Ramasamy DP; Davis MD; Steinerman JR; Khan O
J Neuroimaging; 2015; 25(6):989-95. PubMed ID: 26394270
[TBL] [Abstract][Full Text] [Related]
12. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
Zivadinov R; Dwyer M; Barkay H; Steinerman JR; Knappertz V; Khan O
J Neurol; 2015 Mar; 262(3):648-53. PubMed ID: 25542295
[TBL] [Abstract][Full Text] [Related]
13. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
[TBL] [Abstract][Full Text] [Related]
14. Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Phillips G; Guo S; Bender R; Havrdová E; Proskorovsky I; Vollmer T
Mult Scler Relat Disord; 2016 Mar; 6():66-72. PubMed ID: 27063626
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
Krueger JG; Kircik L; Hougeir F; Friedman A; You X; Lucas N; Greenberg SJ; Sweetser M; Castro-Borrero W; McCroskery P; Elkins J
Adv Ther; 2016 Jul; 33(7):1231-45. PubMed ID: 27251051
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
[TBL] [Abstract][Full Text] [Related]
17. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
18. Evolution of acute "black hole" lesions in patients with relapsing-remitting multiple sclerosis.
Kostic D; Dincic E; Jovanovski A; Kostic S; Rancic N; Georgievski-Brkic B; Misovic M; Koprivsek K
Acta Neurol Belg; 2023 Jun; 123(3):831-838. PubMed ID: 35397094
[TBL] [Abstract][Full Text] [Related]
19. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
Miller DH; Soon D; Fernando KT; MacManus DG; Barker GJ; Yousry TA; Fisher E; O'Connor PW; Phillips JT; Polman CH; Kappos L; Hutchinson M; Havrdova E; Lublin FD; Giovannoni G; Wajgt A; Rudick R; Lynn F; Panzara MA; Sandrock AW;
Neurology; 2007 Apr; 68(17):1390-401. PubMed ID: 17452584
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials.
Traboulsee A; Li D; Tam R; Zhao G; Riddehough A; Fang J; Dangond F; Kappos L;
Mult Scler J Exp Transl Clin; 2017; 3(4):2055217317745340. PubMed ID: 29276624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
